engineered GM-CSF

Engineered GM-CSF is a modified recombinant cytokine designed to localize within the tumor microenvironment (TME) to enhance antitumor immunity while minimizing systemic side effects. Specifically developed as a stroma-binding protein (utilizing a collagen-binding domain), this agent targets the granulocyte-macrophage colony-stimulating factor receptor (GM-CSFR) on myeloid cells. By binding to the tumor extracellular matrix, it polarizes tumor-associated macrophages (TAMs) and dendritic cells (DCs) from an immunosuppressive (M2-like) state to a proinflammatory, antitumorigenic (M1-like) phenotype. This polarization facilitates improved antigen presentation and T-cell activation. Research, particularly from the University of Chicago, has demonstrated that engineered GM-CSF potently synergizes with other localized cytokines like IL-12 to eradicate solid tumors and overcome resistance to checkpoint inhibitors in preclinical models.

Other names

stroma-binding GM-CSFcollagen-binding GM-CSFtumor stroma-binding granulocyte-macrophage colony-stimulating factor